type 2 diabetes Archives
Therapeutic targets for diabetes
May. 3, 2017—Vanderbilt investigators have identified novel regulators of insulin-producing beta-cell proliferation and survival, suggesting new targets for the treatment of type 2 diabetes.
Diabetes management and low income
Apr. 6, 2016—Adherence to medication was the only self-care activity independently associated with glycemic control in a low-income population.
Fighting type 2 diabetes with FGF1
Nov. 18, 2015—The growth factor FGF1 induces the growth of new insulin-producing beta cells and may help treat type 2 diabetes.
Lymphocyte study reveals obesity clues
Oct. 16, 2014—Vanderbilt University researchers are closer to understanding the link between obesity, chronic inflammation and type 2 diabetes.
Study tracks insulin’s risks as second-line diabetes medication
Jun. 12, 2014—In an observational study by researchers at Vanderbilt University Medical Center, adults with type 2 diabetes who take insulin in addition to the recommended first-line drug therapy, metformin, had a 30 percent higher risk of heart attack, stroke or death when compared to similar patients who instead augment their metformin regimen with a sulfonylurea.
Matrix remodeling and insulin resistance
Apr. 10, 2014—The extracellular matrix that surrounds cells plays a role in the development of insulin resistance.
Bariatric surgery’s metabolic impact to be explored
Dec. 19, 2013—Vanderbilt University researchers have received a two-year, $1.2 million grant from the National Institutes of Health (NIH) to study a mouse model of the metabolic and hormonal changes caused by bariatric surgery.
Study sheds new light on type 2 diabetes development
Oct. 24, 2013—Inactivation by oxidative stress of specific transcription factors essential for pancreatic islet beta cell function is a key event in the development of type 2 diabetes, Vanderbilt University researchers and their colleagues have found.
Antipsychotic drug use in children for mood/behavior disorders increases type 2 diabetes risk
Aug. 22, 2013—Prescribing “atypical” antipsychotic medications to children and young adults with behavioral problems or mood disorders may put them at unnecessary risk for type 2 diabetes, a Vanderbilt University Medical Center study shows.
